On December 28, the half day net inflow of northward funds exceeded 1 billion yuan. The performance of the three major indexes in the A-share market was differentiated, led by the home appliances and computer industries, and two new shares listed today broke. The development pharmaceutical industry in the Hong Kong stock market plunged, falling more than 80% during the session and 67.52% as of midday closing.
As of midday closing, the Shanghai Composite Index fell 0.16%, the Shenzhen Component Index rose 0.10% and the gem index rose 0.10%. The half day turnover of the two markets exceeded 600 billion yuan, including 243.057 billion yuan in Shanghai and 364.063 billion yuan in Shenzhen.
China Industrial Securities Co.Ltd(601377) believes that the current cross year market is not over, the market logic is still established, and continues to be realized and strengthened. Therefore, hold the bumps and beat the short with the long, and the cross-year market is not finished to be continued.
home appliance industry led the rise
In today's market, individual stocks rose more and fell less. As of the close, the number of rising stocks in the two cities was 2368, 47 stocks rose by the limit, 2077 stocks fell and 5 stocks fell by the limit.
Among the Shenwan level industries, household appliances, computers and social service industries led the increase, rising by 2.11%, 1.60% and 1.21% respectively; Coal, public utilities and building decoration industries led the decline, down 3.39%, 2.39% and 1.55% respectively.
In the computer equipment sector, Tatwah Smartech Co.Ltd(002512) , Szzt Electronics Co.Ltd(002197) , Cashway Fintech Co.Ltd(603106) limit. In the small household appliance sector, Guangdong Xinbao Electrical Appliances Holdings Co.Ltd(002705) rose by the limit and Xiamen Comfort Science & Technology Group Co.Ltd(002614) rose by more than 8%.
Fu Rong fund research department general manager Lang Chengcheng believes that the market is still relatively benign interval, short-term recommendations relatively balanced configuration, including automotive intelligence, VR/AR, folding screens and other new consumer cycle products under the bottom of the market reversal market, the expected economic stability of the Baijiu, gold melting plate valuation switch market, based on the bottom line of the financial policy is expected to "real estate chain" plate. And attach importance to the configuration opportunities of photovoltaic, military industry and semiconductor callback of high boom growth track.
one of the two new shares lost more than 6000 yuan
Today, four new shares of youningwei, oney electronics, Kelun electronics and Nanmo biology are listed, of which oney electronics and Nanmo biology have broken. As of midday closing, n oni and N Nanmo fell 11.00% and 15.13% respectively.
The broken n south model is also the stock with the largest decline in the two markets this morning. According to the announcement of the exchange, Nanmo biology is listed on the science and Innovation Board of Shanghai Stock Exchange today. The company's securities code is 688265, the issue price is 84.62 yuan / share, and the issue price earnings ratio is 201.59 times.
According to the issuance plan of Nanmo biology, it was originally planned to raise 400 million yuan, and finally raised 1.249 billion yuan, with a total fund of 1.649 billion yuan.
According to the announcement of the issuance results previously disclosed by Nanmo biology, online investors gave up the subscription of 119300 shares, with an amount of 10.0958 million yuan; The number of offline investors giving up subscription is 0 and the amount is 0.
Based on the lowest price of 70.66 yuan / share in n south model, the loss amount of the first signing can reach up to 6980 yuan. Based on the lowest price of 54 yuan / share, the loss amount of the first signing can reach 6090 yuan. Market participants said that the reason for the break of Nanmo biology is that the issue price is too high.
Kaifa pharmaceutical plunged more than 80%
As a star stock in the Hong Kong stock market this year, kaifa-b has the largest increase of 750.86% this year. With today's sharp decline, the cumulative increase this year was once negative. Based on the latest quotation of HK $14.68 / share, Kaifa's increase in 2021 is only 40.34%.
As of noon closing, Kaifa pharmaceutical-b fell 67.52%, with a turnover of HK $860 million and a market value of HK $5.69 billion, with the largest intraday decline of 84.71%.
It is worth noting that under the sharp decline, some people were radical bottom hunters. 26000 hands were traded at the lowest price of HK $6.91 per share in early trading, with a floating profit of more than 100%. Under the trading rules of Hong Kong stocks T + 0, this income can be cashed today.
The sudden slump stunned investors. In the development of pharmaceutical-b-share bar, some investors said, "what's the situation?" Some investors said: "bottom reading."
On December 27, kaifa-b announced the progress of phase III clinical trial of covid-19 in the treatment of mild to moderate disease non hospitalized covid-19 patients. It said that according to the interim analysis data of 348 covid-19 patients, due to the small number of events and not reaching statistical significance, the company plans to adjust the clinical trial scheme for patient recruitment.
In the view of the industry, from the results published so far, the phase III clinical trial was frustrated, which was the fuse leading to today's sharp decline.
<divvoteid="14962" votetitle="%u3010%u80A1%u6C11%u8C03%u67E5%u95EE%u5377%u30112021%uFF0C%u4F60%u8D5A%u94B1%u4E86%u5417%uFF1F" >
(China Securities Journal)
